rhinosinusitis%20-%20acute,%20bacterial
RHINOSINUSITIS - ACUTE, BACTERIAL
Acute bacterial rhinosinusitis is the mucosal inflammation of the nose and paransal sinuses caused by bacteria lasting >10 days for up to 4 weeks or symptoms worsening for 5-7 days and is <12 weeks with complete resolution of symptoms.
It is often preceded by a viral upper respiratory tract infection.
Signs and symptoms are nonspecific and typically difficult to differentiate from viral upper respiratory tract infection.
There is fever with nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without facial pressure/pain/fullness and reduction/loss of smell.
Streptococcus pneumoniae and unencapsulated strains of Haemophilus influenzae cause half of acute rhinosinusitis cases.
Drug Information

Indication: Relief of mild to moderate pain & fever.

Indication: Short-term treatment of upper & lower resp tract, skin & soft tissue, GUT infections. Tab & inj Sh...

Indication: Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired & nosoco...

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Infections of the resp tract, middle ear (otitis media), paranasal sinuses (sinusitis) especially caused by gm...

Indication: Upper & lower resp tract infection, upper & lower UTI, peritonitis, cholecystitis, cholangitis & o...

Indication: Upper & lower resp tract infections including sinusitis, otitis media & epiglottitis, bacterial pneumo...

Indication: Infections caused by susceptible organisms in lower resp tract (eg, bronchitis, pneumonia), skin & soft ti...

Indication: Tab/powd for oral susp Lower resp tract infections including bronchitis & pneumonia; skin & soft tissu...

Indication: Symptomatic relief of nasal & nasopharyngeal congestion. Facilitates intranasal exam or before nasal surge...

1  /  29
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Jun 2019
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.